Evaluation of the clinical efficiency of COVID drug treatment of clinical-paraclinical parameters in a critical case of COVID-19 with severe pulmonary dysfunction after cesarean section

On 11 March 2020 World Health Organization declared the Coronavirus disease 2019 (COVID-19) caused by a novel coronavirus (SARS–CoV–2, 2019 – nCoV) a global pandemic. After a year, there are still many unknowns about peripartum women suffering from COVID – 19. In some pregnant women, respiratory failure can rapidly progress to acute respiratory distress syndrome (ARDS) which is requiring extracorporeal membrane oxygenation (ECMO) as a life – saving therapy. This motivated our team to report the case of a 22-year-old pregnant woman suffering from obesity, gestational hypertension with a severe COVID – 19 forms associated with ARDS. We want to highlight the potential benefits of therapeutic management, after an analysis of clinical and paraclinical parameters, especially because the patient was discharge after 40 days with no major complications. The urgent delivery, early initiation of ECMO and the complex pharmacological therapy (including Remdesivir) resulted in favorable maternal– fetal outcomes.